Bencis also said that it will launch a mandatory public offer at a price of €5.85 per share for Xeikon after the company completes the buyback of its own shares.
The firm added that it plans to launch a squeeze out of the remaining Xeikon shares after the application period for the mandatory public offer.
Bencis and XBC have already secured debt and mezzanine funding for the mandatory offer.
Last month Gimv exited Endosense to St.Jude Medical in a deal that could value the medical technology business at up to CHF309m ($225.8m).
Copyright © 2013 AltAssets